Oculis (NASDAQ:OCS) Trading Up 8.3%

Oculis Holding AG (NASDAQ:OCS) traded up 8.3% during trading on Monday . The company traded as high as $13.16 and last traded at $13.02. 82,027 shares changed hands during mid-day trading, an increase of 74% from the average session volume of 47,052 shares. The stock had previously closed at $12.02.

Analysts Set New Price Targets

OCS has been the subject of several research reports. Wedbush restated an “outperform” rating and set a $29.00 price objective on shares of Oculis in a research note on Wednesday, March 6th. HC Wainwright decreased their price target on Oculis from $29.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, April 24th. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Oculis in a research note on Tuesday, March 19th. Finally, Robert W. Baird reduced their price target on Oculis from $64.00 to $35.00 and set an “outperform” rating for the company in a report on Tuesday, March 19th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $29.14.

Oculis Price Performance

The company has a 50-day moving average of $11.87 and a 200 day moving average of $11.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.29 and a current ratio of 5.29.

Oculis (NASDAQ:OCS) last released its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.28 million. As a group, equities analysts predict that Oculis Holding AG will post -1.72 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OCS. Searle & CO. purchased a new position in shares of Oculis during the 4th quarter worth $112,000. abrdn plc purchased a new stake in shares of Oculis during the 4th quarter valued at approximately $15,980,000. Compagnie Lombard Odier SCmA raised its position in Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after purchasing an additional 30,750 shares during the period. Finally, Wolverine Asset Management LLC acquired a new position in Oculis in the third quarter valued at about $77,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.